{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:11:18Z","timestamp":1781521878561,"version":"3.54.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0014086","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000}}],"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-CSAINV22jul-0009"],"award-info":[{"award-number":["MOH-CSAINV22jul-0009"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Human Infection Challenge Vaccine (HIC-Vac) Development Network","award":["WHRR_PB0021"],"award-info":[{"award-number":["WHRR_PB0021"]}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The immunopathogenesis of dengue infection and immune correlates of protection are uncertain, no therapeutic anti-viral is available, and the long-term risks of severe breakthrough infection after vaccination remain of concern. Dengue controlled human infection models (DCHIM) have found increasing utility and have the potential to address these unmet needs. We reviewed the clinical, biochemical and immunologic features of modern day DCHIMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review protocol was developed and registered with PROSPERO [CRD42024558534]. We searched MEDLINE, Cochrane and Embase for controlled human infection studies using attenuated dengue virus strains from January 2000 \u2013 December 2025. No restriction was placed on study setting (dengue endemic\/non-endemic) or whether the study was conducted in seronegative or seropositive individuals. The primary outcome was the proportion of inoculated participants who developed viraemia (\u2018attack rate\u2019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our search yielded 1181 results, and identified 11 published studies, recruiting 248 participants aged 18\u201355 years. All studies were performed in non-dengue endemic areas and were models of primary dengue. Four studies challenged previously vaccinated individuals, and one utilised DCHIM to assess antiviral efficacy. Attenuated dengue virus strains of all four DENV 1\u20134 serotypes were utilised as challenge agents. Attack rate across all serotypes was 50\u2013100% in seronegative participants and 0\u201383% in previously vaccinated participants and was strain-dependent. Clinical and biochemical features of dengue fever varied between strains, with peak viral load and probability of fever being highly correlated (r\u2009=\u20090\u00b791, p\u2009&lt;\u20090\u00b701). There were no serious adverse event reported, and 9 (4%) participants met protocol criteria for hospitalisation. Viral and\/or immune evidence of disease enhancement was observed in 5\/81 (7%) of challenged seropositive participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DCHIMs of primary dengue are a valuable and safe tool that has supported vaccine development. Further work is needed to expand DCHIMs to endemic settings and as a model of secondary dengue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0014086","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:36:34Z","timestamp":1773336994000},"page":"e0014086","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review of dengue controlled human infection studies: safety, viral kinetics and immunology"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8050-9357","authenticated-orcid":true,"given":"Srishti","family":"Chhabra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po Ying","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Sin","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby Edward","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"9","key":"pntd.0014086.ref001","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00705-023-05835-1","article-title":"Renaming of the genus Flavivirus to Orthoflavivirus and extension of binomial species names within the family Flaviviridae","volume":"168","author":"TS Postler","year":"2023","journal-title":"Arch Virol"},{"issue":"8179","key":"pntd.0014086.ref002","article-title":"Interactions between climate change, urban infrastructure and mobility are driving dengue emergence in Vietnam","volume":"14","author":"R Gibb","year":"2023","journal-title":"Nature Communications"},{"key":"pntd.0014086.ref003","article-title":"Disease Outbreak News; Dengue \u2013 Global situation","author":"(WHO) WHO","year":"2023"},{"issue":"15","key":"pntd.0014086.ref004","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"CP Simmons","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"pntd.0014086.ref005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/cid\/ciac820","article-title":"A systematic review of human challenge trials, designs, and safety","volume":"76","author":"J Adams-Phipps","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0014086.ref006","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"AB Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"pntd.0014086.ref007","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4269\/ajtmh.14-0132","article-title":"Review article: research on dengue during World War II revisited","volume":"91","author":"GE Snow","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"pntd.0014086.ref008","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines","volume":"207","author":"W Sun","year":"2013","journal-title":"J Infect Dis"},{"issue":"13","key":"pntd.0014086.ref009","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.vaccine.2013.12.040","article-title":"Evaluation of dengue virus strains for human challenge studies","volume":"32","author":"MP Mammen","year":"2014","journal-title":"Vaccine"},{"key":"pntd.0014086.ref010","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu174","article-title":"The human dengue challenge experience at the Walter Reed Army Institute of Research","volume":"209","author":"AG Lyons","year":"2014","journal-title":"J Infect Dis"},{"key":"pntd.0014086.ref011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2020.09.005","article-title":"Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003\/TV005","volume":"43","author":"AP Durbin","year":"2020","journal-title":"Curr Opin Virol"},{"issue":"5","key":"pntd.0014086.ref012","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults","volume":"390","author":"EG Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"pntd.0014086.ref013","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2500179","article-title":"Daily Mosnodenvir as dengue prophylaxis in a controlled human infection model","volume":"393","author":"AP Durbin","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"pntd.0014086.ref014","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/s41564-024-01668-z","article-title":"Low-dose dengue virus 3 human challenge model: a phase 1 open-label study","volume":"9","author":"AT Waickman","year":"2024","journal-title":"Nat Microbiol"},{"key":"pntd.0014086.ref015","article-title":"Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines","author":"KK Pierce","year":"2024","journal-title":"medRxiv"},{"issue":"668","key":"pntd.0014086.ref016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5019","article-title":"Evolution of inflammation and immunity in a dengue virus 1 human infection model","volume":"14","author":"AT Waickman","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"pntd.0014086.ref017","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiaa351","article-title":"A phase 1, open-label assessment of a dengue virus-1 live virus human challenge strain","volume":"223","author":"TP Endy","year":"2021","journal-title":"J Infect Dis"},{"issue":"50","key":"pntd.0014086.ref018","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1016\/j.vaccine.2015.09.052","article-title":"Dengue human infection models to advance dengue vaccine development","volume":"33","author":"CP Larsen","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"pntd.0014086.ref019","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1473-3099(24)00100-2","article-title":"Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial","volume":"24","author":"KE Lyke","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pntd.0014086.ref020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173328","article-title":"TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies","volume":"134","author":"KK Pierce","year":"2024","journal-title":"J Clin Invest"},{"issue":"330","key":"pntd.0014086.ref021","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"BD Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"issue":"10","key":"pntd.0014086.ref022","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/infdis\/jiaa603","article-title":"Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial","volume":"223","author":"L Lin","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"pntd.0014086.ref023","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","article-title":"A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes","volume":"65","author":"JM Troyer","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0014086.ref024","article-title":"Controlled Dengue Human Infection Model in Thailand","author":"Division of Dengue Hemorrhagic Fever Research FoMSH, Mahidol University"},{"key":"pntd.0014086.ref025","article-title":"Clinicaltrials.gov: Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169","year":"2022"},{"issue":"6303","key":"pntd.0014086.ref026","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment","volume":"353","author":"NM Ferguson","year":"2016","journal-title":"Science"},{"key":"pntd.0014086.ref027","doi-asserted-by":"crossref","first-page":"29201","DOI":"10.1038\/srep29201","article-title":"Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing higher fusion against antiviral responses","volume":"6","author":"J Flipse","year":"2016","journal-title":"Sci Rep"},{"issue":"6365","key":"pntd.0014086.ref028","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"LC Katzelnick","year":"2017","journal-title":"Science"},{"issue":"10","key":"pntd.0014086.ref029","article-title":"Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial","volume":"5","author":"KE Lyke","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"pntd.0014086.ref030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.1812055115","article-title":"Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies","volume":"116","author":"R Raut","year":"2019","journal-title":"Proc Natl Acad Sci U S A"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0014086","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:46:51Z","timestamp":1773856011000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014086"}},"subtitle":[],"editor":[{"given":"Puneet","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014086","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}